A H Xiang1, R M Watanabe, T A Buchanan. 1. Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 5th Floor, Pasadena, CA, 91101, USA, anny.h.xiang@kp.org.
Abstract
AIMS/HYPOTHESIS: Little is known about the performance of surrogates in assessing changes in insulin sensitivity over time. This report compared updated HOMA of insulin sensitivity (HOMA2-%S) and the Matsuda index from OGTTs with minimal model-based estimates of insulin sensitivity (SI) from frequently sampled IVGTTs (FSIGTs) in longitudinal settings and cross-sectional settings. METHODS: Two longitudinal studies were used: one a natural observational study in which 338 individuals were followed for a median of 4 years; one a clinical treatment study in which 97 individuals received pioglitazone treatment and were followed for 1 year. Pairs of OGTTs and FSIGTs were performed at baseline and follow-up. Correlations were computed. Impact of measurement uncertainty was investigated through simulation studies. RESULTS: Correlations between HOMA2-%S and SI from baseline or follow-up data were in the range reported previously (0.61-0.69). By contrast, correlations for changes over time were only 0.35-0.39. The corresponding correlations between the Matsuda index and SI were 0.66-0.72 for cross-sectional data and 0.40-0.48 for longitudinal change. Correlations for changes were significantly lower than the cross-sectional correlations in both studies (p < 0.03). Simulation results demonstrated that the reduced correlations for change were not explained by error propagation, supporting a real limitation of surrogates to fully capture longitudinal changes in insulin sensitivity. CONCLUSIONS/ INTERPRETATION: HOMA and Matsuda indices derived from cross-sectional data should be used cautiously in assessing longitudinal changes in insulin sensitivity.
AIMS/HYPOTHESIS: Little is known about the performance of surrogates in assessing changes in insulin sensitivity over time. This report compared updated HOMA of insulin sensitivity (HOMA2-%S) and the Matsuda index from OGTTs with minimal model-based estimates of insulin sensitivity (SI) from frequently sampled IVGTTs (FSIGTs) in longitudinal settings and cross-sectional settings. METHODS: Two longitudinal studies were used: one a natural observational study in which 338 individuals were followed for a median of 4 years; one a clinical treatment study in which 97 individuals received pioglitazone treatment and were followed for 1 year. Pairs of OGTTs and FSIGTs were performed at baseline and follow-up. Correlations were computed. Impact of measurement uncertainty was investigated through simulation studies. RESULTS: Correlations between HOMA2-%S and SI from baseline or follow-up data were in the range reported previously (0.61-0.69). By contrast, correlations for changes over time were only 0.35-0.39. The corresponding correlations between the Matsuda index and SI were 0.66-0.72 for cross-sectional data and 0.40-0.48 for longitudinal change. Correlations for changes were significantly lower than the cross-sectional correlations in both studies (p < 0.03). Simulation results demonstrated that the reduced correlations for change were not explained by error propagation, supporting a real limitation of surrogates to fully capture longitudinal changes in insulin sensitivity. CONCLUSIONS/ INTERPRETATION: HOMA and Matsuda indices derived from cross-sectional data should be used cautiously in assessing longitudinal changes in insulin sensitivity.
Authors: Richard N Bergman; Daniel J Zaccaro; Richard M Watanabe; Steven M Haffner; Mohammed F Saad; Jill M Norris; Lynne E Wagenknecht; James E Hokanson; Jerome I Rotter; Steven S Rich Journal: Diabetes Date: 2003-08 Impact factor: 9.461
Authors: Sudha S Shankar; Adrian Vella; Ralph H Raymond; Myrlene A Staten; Roberto A Calle; Richard N Bergman; Charlie Cao; Danny Chen; Claudio Cobelli; Chiara Dalla Man; Mark Deeg; Jennifer Q Dong; Douglas S Lee; David Polidori; R Paul Robertson; Hartmut Ruetten; Darko Stefanovski; Maria T Vassileva; Gordon C Weir; David A Fryburg Journal: Diabetes Care Date: 2016-07-12 Impact factor: 19.112
Authors: Anu Sharma; Ron T Varghese; Meera Shah; Chiara Dalla Man; Claudio Cobelli; Robert A Rizza; Kent R Bailey; Adrian Vella Journal: J Clin Endocrinol Metab Date: 2018-01-01 Impact factor: 5.958
Authors: Tamara S Hannon; Steven E Kahn; Kristina M Utzschneider; Thomas A Buchanan; Kristen J Nadeau; Philip S Zeitler; David A Ehrmann; Silva A Arslanian; Sonia Caprio; Sharon L Edelstein; Peter J Savage; Kieren J Mather Journal: Diabetes Obes Metab Date: 2017-06-22 Impact factor: 6.577
Authors: Jon D Adams; Aoife M Egan; Marcello C Laurenti; Daniel Schembri Wismayer; Kent R Bailey; Claudio Cobelli; Chiara Dalla Man; Adrian Vella Journal: Am J Physiol Endocrinol Metab Date: 2021-10-18 Impact factor: 4.310
Authors: Meera Shah; Ron T Varghese; John M Miles; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Kent R Bailey; Robert A Rizza; Adrian Vella Journal: Diabetes Date: 2015-11-02 Impact factor: 9.461
Authors: Rena M Pollack; Nir Barzilai; Valentin Anghel; Ameya S Kulkarni; Aaron Golden; Pilib O'Broin; David A Sinclair; Michael S Bonkowski; Alexander J Coleville; Danielle Powell; Sharon Kim; Ruin Moaddel; Daniel Stein; Kehao Zhang; Meredith Hawkins; Jill P Crandall Journal: J Gerontol A Biol Sci Med Sci Date: 2017-11-09 Impact factor: 6.053
Authors: Nicholette D Palmer; Lynne E Wagenknecht; Carl D Langefeld; Nan Wang; Thomas A Buchanan; Anny H Xiang; Hooman Allayee; Richard N Bergman; Leslie J Raffel; Yii-Der Ida Chen; Talin Haritunians; Tasha Fingerlin; Mark O Goodarzi; Kent D Taylor; Jerome I Rotter; Richard M Watanabe; Donald W Bowden Journal: Diabetes Date: 2016-05-03 Impact factor: 9.461